Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Evaluation of the Efficacy and Tolerability of Oral Ciprofloxacin used in the Comprehensive Treatment of External Bacterial Otitis: An Observational Prospective Study.

Tytuł:
Evaluation of the Efficacy and Tolerability of Oral Ciprofloxacin used in the Comprehensive Treatment of External Bacterial Otitis: An Observational Prospective Study.
Autorzy:
Gurov AV; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Kriukov AI; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Kunelskaya VY; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Isotova GN; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Shadrin GB; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Luchsheva YV; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Yakimov VO; The Sverzhevskiy Otorhinolaryngology Healthcare Research Institute, Moscow Department of Healthcare, Moscow, Russian Federation.
Garg A; Emerging Markets, Global Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
Akku SP; Emerging Markets, Global Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
Gupta N; Global Medical Affairs, Dr. Reddy's Laboratories Ltd., Hyderabad, Telangana, India.
Źródło:
International archives of otorhinolaryngology [Int Arch Otorhinolaryngol] 2017 Oct; Vol. 21 (4), pp. 329-335. Date of Electronic Publication: 2017 Feb 17.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Oct. 2013- : Rio de Janeiro, Brazil : Thieme
Original Publication: [São Paulo, SP : Fundação Otorrinolaringologia]
References:
Australas Med J. 2014 Oct 31;7(10):392-9. (PMID: 25379060)
BMJ Clin Evid. 2010 Aug 03;2010:null. (PMID: 21418684)
CMAJ. 1994 Mar 1;150(5):669-76. (PMID: 8313286)
BMJ. 2003 Nov 22;327(7425):1201-5. (PMID: 14630756)
Eur Arch Otorhinolaryngol. 2012 Mar;269(3):753-6. (PMID: 21761191)
Clin Otolaryngol Allied Sci. 1992 Apr;17(2):150-4. (PMID: 1587031)
Br J Gen Pract. 2001 Jul;51(468):533-8. (PMID: 11462312)
Curr Med Res Opin. 2011 Oct;27(10):2053-60. (PMID: 21919557)
Adv Ther. 2007 May-Jun;24(3):671-5. (PMID: 17660178)
Am Fam Physician. 2006 Nov 1;74(9):1510-6. (PMID: 17111889)
Am Fam Physician. 2001 Mar 1;63(5):927-36, 941-2. (PMID: 11261868)
Otolaryngol Head Neck Surg. 2014 Feb;150(1 Suppl):S1-S24. (PMID: 24491310)
Contributed Indexing:
Keywords: ciprofloxacin; observational study; otitis; pseudomonas; staphylococcus
Entry Date(s):
Date Created: 20171012 Latest Revision: 20201001
Update Code:
20240105
PubMed Central ID:
PMC5629078
DOI:
10.1055/s-0037-1598648
PMID:
29018494
Czasopismo naukowe
Introduction  Otitis Externa is common ear infection with a prevalence of 1%. Objective  The objective of this study is to evaluate the clinical and microbiological efficacy and safety profile with oral ciprofloxacin in the external bacterial otitis (EBO) management. Methods  This is a prospective observational study conducted with EBO outpatients referred to the otorhinolaryngology center in Moscow between March and August 2013. Our study included patients from two cohorts, acute external bacterial otitis (AEBO) - Group 1 - and exacerbation of chronic otitis externa (CEBO) - Group 2. We administered Ciprofloxacin 500 mg twice daily with standard topical EBO treatment for up to 10 days. Patients underwent evaluation on study visit days 1, 3, 5, and 10 for the severity. Bacteriological examination of ear canal cultures took place on Day 1 and Day 10. Results  We collected data from 60 EBO outpatients (AEBO: N  = 30 and CEBO: N  = 30). Swimming was the major risk factor associated with the disease in addition to the most common pathogenic organisms - Staphylococcus aureus and Pseudomonas aeruginosa . was We attained complete resolution of the inflammatory process in 28 (93%) and 27 (90%) patients in the AEBO and CEBO group, respectively. We confirmed this by microbiological test with almost complete eradication of the causative organisms. Overall, we observed good positive dynamics of ear canal with no major side effects. Conclusion  We found that Ciprofloxacin 500 mg, when administered orally twice daily for 7 to 10 days in otitis externa patients is clinically and microbiologically effective and comparatively safer than other antimicrobials.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies